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2 
ABSTRACT  25 
Abnormal protein kinase C (PKC) function contributes to many pathophysiological processes 26 
relevant for Alzheimer’s disease (AD), such as amyloid precursor protein (APP) processing. 27 
Phorbol esters and other PKC activators have been demonstrated to enhance the secretion of 28 
soluble APPα (sAPPα), reduce the levels of β-amyloid (Aβ), induce synaptogenesis, and 29 
promote neuroprotection. We have previously described isophthalate derivatives as a 30 
structurally simple family of PKC activators. Here, we characterized the effects of isophthalate 31 
derivatives HMI-1a3 and HMI-1b11 on neuronal viability, neuroinflammatory response, 32 
processing of APP and dendritic spine density and morphology in in vitro. HMI-1a3 increased 33 
the viability of embryonic primary cortical neurons and decreased the production of the 34 
pro-inflammatory mediator TNFα, but not that of nitric oxide, in mouse neuron-BV2 microglia 35 
co-cultures upon LPS- and IFN-γ-induced neuroinflammation. Furthermore, both HMI-1a3 36 
and HMI-1b11 increased the levels of sAPPα relative to total sAPP and the ratio of Aβ42/Aβ40 37 
in human SH-SY5Y neuroblastoma cells. Finally, bryostatin-1, but not HMI-1a3, increased the 38 
number of mushroom spines in proportion to total spine density in mature mouse hippocampal 39 
neuron cultures. These results suggest that the PKC activator HMI-1a3 exerts neuroprotective 40 
functions in the in vitro models relevant for AD by reducing the production of TNFα and 41 
increasing the secretion of neuroprotective sAPPα.  42 
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1. Introduction 48 
Alzheimer’s disease (AD) is the most common cause of dementia in the aging population 49 
without existing intervention approaches to halt or even slow down the disease progression. A 50 
central pathological feature of AD includes accumulation of toxic and aggregation-prone β-51 
amyloid (Aβ) peptides. Aβ causes synaptic dysfunction, activation of microglia and astrocytes, 52 
oxidative and inflammatory stress, and formation of intraneuronal neurofibrillary tangles 53 
(NFTs) consisting of hyperphosphorylated tau (Hardy, 2002). Aβ is generated from amyloid 54 
precursor protein (APP) as a result of sequential cleavages by β-site-APP-cleaving-enzyme-1 55 
(BACE1) and γ-secretase (De Strooper and Annaert, 2000). Depending on the site of the γ-56 
secretase cleavage, Aβ peptides of different lengths are generated and particularly Aβ42 is 57 
prone to aggregate (Selkoe, 1994). In contrast, α-secretase (ADAM10 and ADAM17) cleavage 58 
preceding the γ-secretase cleavage of APP leads to the extracellular release of soluble APPα 59 
(sAPPα) and a C-terminal fragment (C83) on the membrane, thus precluding the generation of 60 
intact Aβ peptide (De Strooper and Annaert, 2000; Haass et al., 1993). Increased production of 61 
sAPPα has been demonstrated to have many beneficial effects, including stimulation of neurite 62 
outgrowth, cell proliferation, synaptic density, memory retention, and neuroprotection 63 
(reviewed in (Müller et al., 2017)). The hyperphosphorylation of tau protein leads to 64 
accumulation of intracellular NFTs and neuronal dysfunction (Grundke-Iqbal et al., 1986a, 65 
1986b).  66 
 Several signaling pathways are known to regulate the pathophysiological processes 67 
involved in the development or progress of AD, one of them being protein kinase C (PKC) 68 
(Choi et al., 2006; Crews and Masliah, 2010; Godoy et al., 2014; Lucke-Wold et al., 2015). 69 
PKC is a family of serine/threonine kinases with at least 10 isoforms found in mammals 70 
(Newton, 2003). These isoforms are divided into three classes based on their activators. 71 
Classical PKCs require both Ca2+ and diacylglycerol (DAG) for activation whereas novel PKCs 72 
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are independent of Ca2+, but they require DAG. On the other hand, atypical PKCs are activated 73 
by mechanisms independent of DAG and Ca2+. PKC has been called a “memory kinase” and it 74 
has been widely studied in relation to its central role in memory formation in both normal and 75 
pathological settings, such as AD models (Lucke-Wold et al., 2015). As PKC regulates several 76 
processes linked to AD pathophysiology, its pharmacological activation is considered a 77 
potential therapeutic strategy for treating AD (Alkon et al., 2007; Sun and Alkon, 2012, 2010; 78 
Talman et al., 2016). A number of studies have shown that PKC activation directs APP 79 
processing to the non-pathogenic α-secretase pathway and thereby increases the production of 80 
neuroprotective sAPPα and reduces the production of neurotoxic Aβ species both in vitro and 81 
in vivo (Alkon et al., 2007; Buxbaum et al., 1990; Etcheberrigaray et al., 2004; Jacobsen et al., 82 
1994; Kozikowski et al., 2003). Activation of PKC has also been suggested to inhibit Aβ 83 
accumulation by increasing its degradation through upregulation of gelsolin and activation of 84 
endothelin-converting enzyme (Choi et al., 2006; Ji et al., 2010). Additionally, PKC activation 85 
has been reported to protect neurons from Aβ cytotoxicity (Garrido et al., 2002; Han et al., 86 
2004). Besides the β-amyloid pathology, activated PKC also inhibits tau hyperphosphorylation 87 
by phosphorylating and inactivating glycogen synthase kinase 3β (GSK3β), a central kinase 88 
phosphorylating tau (Isagawa et al., 2000). Furthermore, PKC activation has been shown to 89 
induce neurite elongation (Shirai et al., 2008; Yang et al., 2010) and synaptogenesis (Sen et al., 90 
2016) and to restore mushroom spine synapses (Hongpaisan et al., 2013), indicating that PKC 91 
activation might even exhibit neurorestorative potential.  92 
 Pharmacological PKC activation can be achieved by targeting its regulatory C1 domain, 93 
which is also the binding site for the physiological activator DAG. Several families of C1 94 
domain-targeting PKC agonists, such as phorbol esters, bryostatins, DAG lactones and 95 
benzolactams, have been described  and investigated in the in vitro and in vivo models of AD 96 
(Boije af Gennäs et al., 2011; Talman et al., 2016). Most PKC activators are however scarce in 97 
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natural sources and highly complex in their chemical structure, making them expensive to 98 
isolate in sufficient quantities and difficult to synthesize. Furthermore, in cellular context 99 
prolonged activation of PKC with ultrapotent agonists, such as phorbol esters, leads to 100 
dephosphorylation and subsequent degradation of PKC protein, thus eventually resulting in 101 
diminished PKC activity (Newton, 2003). We have previously developed and reported a novel 102 
group of C1 domain-targeted PKC modulators, derivatives of 5-(hydroxymethyl)isophthalic 103 
acid, which are easy to synthesize from commercially available starting material (Boije af 104 
Gennäs et al., 2009). The best-characterised derivatives, namely HMI-1a3 and HMI-1b11, 105 
promoted neurite outgrowth in SH-SY5Y neuroblastoma cells and HMI-1b11 was shown to 106 
induce PKC-dependent upregulation of the neuronal differentiation marker GAP-43 (Talman 107 
et al., 2013). Instead of testing HMI-1a3 and HMI-1b11 directly in the in vivo models relevant 108 
for AD, we first wanted to elucidate the effects of these isophthalate derivatives on neuronal 109 
viability, neuroinflammatory response, APP processing, and spine morphology using in vitro 110 
models of neuroinflammation and AD.   111 
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2. Material and methods 112 
2.1 Isophthalic acid derivatives 113 
Isophthalic acid derivatives HMI-1a3, HMI-1b11 (which both bind to PKC C1-domain), and 114 
NI-15e (HMI-1a3 analog, which does not bind to C1 domain and was used as a negative 115 
control) were synthesized at the Division of Pharmaceutical Chemistry and Technology, 116 
Faculty of Pharmacy, University of Helsinki (Helsinki, Finland) as described earlier (Boije af 117 
Gennäs et al., 2009).  118 
2.2 Mouse embryonic primary cortical neuron and BV2 microglial cell co-cultures and 119 
treatments 120 
Co-cultures were prepared as described before (Gresa-Arribas et al., 2012; Natunen et al., 121 
2016). Shortly, neuronal cells were isolated from the cortices of embryonic stage 18 (E18) 122 
JAXC57BL/6J-mouse embryos and plated in Neurobasal medium supplemented with B27 123 
(Gibco), penicillin, streptomycin and L-glutamine on poly-D-lysine-coated (PDL; Sigma) 124 
48-well plates at the density of 20 × 104 cells/well. Fresh medium was changed on 5 days in 125 
vitro (DIV5) to feed the cells. Mouse microglial BV2 cells were cultured in RPMI-1640 126 
medium (Sigma) containing 10% FBS, 2 mM L-glutamine and 100 U/ml penicillin and 127 
100 μg/ml streptomycin for two passages. RPMI-medium was replaced with Neurobasal 128 
medium and BV2 cells were gently detached with a cell scraper. BV2 cells were added to 129 
primary cortical neuron cultures in one-to-five ratio (BV2:neurons) at DIV5. Furthermore, all 130 
treatments were implemented for samples without BV2-microglia (neurons only samples). 131 
After one hour, the co-cultured cells were treated with vehicle (0.1% DMSO), anti-132 
inflammatory cytokine IL-10 (50 ng/ml; PeproTech), nitric oxide synthase inhibitor 1400W 133 
(20 µM; Tocris), PKC activator phorbol-12-myristate-13-acetate (PMA; 10 and 100 nM; 134 
Sigma-Aldrich), bryostatin-1 (10 and 100 nM; Sigma-Aldrich),  pan-PKC inhibitor Gö6983 (1 135 
µM; Sigma-Aldrich), and isophthalate derivatives (each with concentrations of 1, 4, 10 and 20 136 
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µM), and let settle for 1 h. Finally, neuroinflammation was induced by treating co-cultures with 137 
200 ng/ml of lipopolysaccharide (LPS) and 20 ng/ml of interferon-γ (IFN-γ) (both from 138 
Sigma-Aldrich). Co-culture media was collected 48 hours after LPS/IFN-γ treatment and 139 
assayed for TNFα, NO, Aβ 1-40, and Aβ 1-42 levels.  140 
2.3 Neuronal viability assay 141 
The MAP2-ABTS assay for neuronal viability was performed as described previously 142 
(Martiskainen et al., 2017; Natunen et al., 2016). Shortly, primary cortical neuron-BV2 143 
microglia co-cultures were fixed in 4% paraformaldehyde (PFA) immediately after removal of 144 
cell media, permeabilized in methanol containing 0.3% H2O2, and subsequently blocked with 145 
blocking solution (PBS, 1% BSA and 10% horse serum; Vector Labs) for 20 min. Neuronal 146 
cells were stained with anti-MAP2 primary antibody (1:2000; Sigma, M9942) overnight at 147 
+4°C. Next day, cells were incubated with biotinylated horse anti-mouse secondary antibody 148 
(1:200; Vector Labs) and ExtrAvidin-HRP tertiary antibody staining (1:500; Sigma) for 1 hour. 149 
After tertiary antibody incubation, cells were washed with PBS and incubated with the ABTS 150 
peroxidase substrate (Vector Labs, #SK-4500) giving the color reaction according to the 151 
manufacturer's instructions. From each well, 150 μl of substrate solution was transferred to a 152 
fresh 96-well plate and absorbance was measured at 405 nm with ELISA microplate reader 153 
(Infinite® M200, Tecan).  154 
2.4 TNFα, NO, and Aβ measurements in primary cortical neuron and BV2 microglial cell 155 
co-cultures 156 
Conditioned media from the cell samples were centrifuged at 10000 × g for 10 min. The levels 157 
of secreted TNFα, Aβ x-40, and Aβ x-42 in the medium was measured using ELISA kits 158 
(Ready-SET-Go mouse-TNFα ELISA kit, eBioscience; Human/Rat β Amyloid 40 and 42, 159 
Wako, Cat no 294-64701/Cat no 292-64501, respectively), following manufacturer’s 160 
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instructions. Aβ results were normalized to neuronal viability as shown previously 161 
(Martiskainen et al., 2017). NO production was assessed using the Griess Reagent Kit for 162 
Nitrite Determination (G-7921, Molecular Probes) following manufacturer’s instructions. 163 
Briefly, co-culture supernatants were collected 48 h after LPS/IFN-γ treatment and incubated 164 
with Griess reagent for 30 min at RT. Optical density at 540 nm was measured using a 165 
microplate reader (Infinite® M200, Tecan). Nitrite concentration was calculated from a sodium 166 
nitrite standard curve. 167 
2.5 SH-SY5Y-APP751 cell culture and treatments 168 
SH-SY5Y human neuroblastoma cells overexpressing human APP751 (SH-SY5Y-APP751) 169 
were grown on 6-well plates (400 000 cells/well) as described previously (Sarajärvi et al., 170 
2009). The next day cells were exposed to HMI-1a3 and HMI-1b11 (both 20 µM), PMA (10 171 
nM), γ-secretase inhibitor N-[N-(3,5 Difluorophenacetyl) L-alanyl]-S-phenylglycine t-butyl 172 
ester (DAPT; Sigma-Aldrich, 10 µM) and bryostatin-1 (10 and 100 nM) in FBS free medium. 173 
Exposure times were 4, 24 and 48 h, after which the media were collected, detached cells spun 174 
down (2000 × g, 2 min at +4°C) and the supernatant collected. The media samples from 4-h 175 
and 24-h time points were used for analyzing secreted amyloid precursor proteins (sAPPs) with 176 
Western blotting and from 48-h time point for determining the Aβ40 and Aβ42 levels with 177 
ELISA (Human/Rat β Amyloid 40 and 42, Wako, Cat no 294-64701/Cat no 292-64501, 178 
respectively). Aβ levels were normalized to total protein levels in the corresponding cell 179 
lysates. After collecting the media, the plates were put on ice, cells washed once with cold PBS 180 
followed by scraping and lysing with a lysis buffer containing 10 mM TRIS-HCl pH 6.8, 1 mM 181 
EDTA, 150 mM NaCl, 0.25% Nonidet P-40 and 1% Triton X-100 complemented with 182 
PHOStop protein phosphatase inhibitor and Complete protease inhibitor cocktails (Roche). 183 
Cell homogenates were centrifuged (16000 × g, 4 min at +4°C) and supernatants collected. To 184 
determine the effect of isophthalates on PKC protein levels, SH-SY5Y naïve cells were used. 185 
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The cells were exposed to isophthalates (HMI-1a3 and HMI-1b11) or PMA (100 nM) for 24 186 
hours in serum-supplemented medium. Cell homogenates were prepared by lysing the cells in 187 
1% SDS (in 50 mM Tris-HCl, pH 7.5) and processed for Western blotting as described below. 188 
 189 
2.6 Western blot analysis 190 
Protein concentrations were measured using Bicinchinonic acid (BCA) protein assay kit 191 
(ThermoFisher Scientific) and equal amounts of protein (20-30 µg) were resolved in 4-12% 192 
gradient Bis-Tris gels (Criterion-XT, Bio-rad) under reducing conditions. Media samples were 193 
resolved under similar conditions, but due to their low protein content, a maximal volume of 194 
media (33 µl) was taken. Samples for PKC level determination were boiled for 5 min with 195 
Laemmli sample buffer (#161-0747, Bio-rad) containing 10 % β-mercaptoethanol (Sigma) and 196 
resolved in 10 % polyacrylamide gels. After transfer to polyvinylidene difluoride (PVDF) 197 
membranes (Trans-Blot Turbo Midi PVDF transfer pack, Bio-rad) or nitrocellulose membranes 198 
(PKC level determination), the membranes were blocked with either 5% milk or 5% BSA 199 
(depending on the antibody) and then incubated overnight with the primary antibodies at +4°C 200 
in a shaker. On the following day, the blots were incubated with secondary antibodies (goat 201 
anti-rabbit, #170-6515, Bio-rad and anti-mouse IgG #7076S, Cell Signaling Technology), 202 
which were subsequently detected with chemiluminescent substrate (SuperSignal West Pico, 203 
#34080, or Supersignal West Femto, #34095, ThermoFisher Scientific) utilizing LAS 3000 204 
Imaging System (Fujifilm) or exposed to film (PKC level determination). Optical densities 205 
(OD) of the bands were measured using ImageJ software (https://imagej.net/Downloads). Cell 206 
lysates from primary cortical neuron-BV2 microglia co-cultures were probed with phospho-207 
S536 NF-B p65 antibody (ab28856, anti-pNF-B p65 (S536) rabbit polyclonal antibody 208 
1:2000, Abcam), total NF-B p65 antibody (ab16502, anti-NF-B p65, rabbit polyclonal 209 
antibody 1:2000, Abcam), and normalized with -actin (ab8226, anti--actin, mouse 210 
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monoclonal antibody 1:1000, Abcam). The blots from cell lysates were probed with APP C-211 
terminus binding antibody (A8717, rabbit anti-APP C-terminus, 1:2000, Sigma). The OD of 212 
these bands were normalized with the OD of GAPDH bands from the same samples (sc47724, 213 
anti-GAPDH, 1:2000, Santa Cruz Biotechnology). The blots from the cell media, were probed 214 
with N-terminus binding antibodies (6E10, mouse anti-Aβ1-16, 1:1000, Biosite, and 22c11, 215 
mouse anti-APP N-terminus, 1:1000, Merck) § For determining the PKC protein levels, all 216 
primary antibodies were from Santa Cruz Biotechnology PKCα (#8393), PKCβI (#8049), 217 
PKCδ (#937) except for PKCε (BD Biosciences, #610085) and were used at 1:1000 dilution. 218 
The experiments were repeated 3 times with 2 parallels. 219 
2.7 Mouse primary hippocampal neuron culture, transient transfection, and spine 220 
morphology analysis 221 
Primary hippocampal neuronal cultures were prepared from 18-day-old mouse JAXC57BL/6J 222 
embryos according to the protocol previously described (Kurkinen et al., 2016). Briefly, single-223 
cell solution (240 000 cells/cm2) was plated on 4-well chamber slides (LabTek) coated with 224 
poly-D-lysine and 30 µg/ml laminin in feeding media composed of Neurobasal medium 225 
supplemented with 2% B27, 0.5 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml 226 
streptomycin. Hippocampal neurons were grown in a cell culture incubator at 37°C in 5% CO2. 227 
Half of the culture media was replaced with fresh feeding media after every 5 days. On DIV19, 228 
mature hippocampal neurons in 4-well chamber slides were transiently transfected with a 229 
mixture containing 2 µl of Lipofectamine 2000 (Invitrogen) and 0.8 µg of enhanced green 230 
fluorescent protein (pEGFP). On DIV20 the cells were treated with 10 µM HMI-1a3, 100 nM 231 
bryostatin-1 (Sigma Aldrich), or 0.1% DMSO (vehicle control) for 2 hours, after which the 232 
hippocampal neurons were fixed in 4% PFA (24 hours after pEGFP transfection). Hippocampal 233 
dendritic spines from GFP-positive neurons were imaged with a Zeiss Axio Observer.Z1 234 
inverted microscope (63 x NA 1.4 oil objective) equipped with Zeiss LSM 800 confocal 235 
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module (Carl Zeiss Microimaging GmbH, Jena, Germany). Serial Z-stacks of optical sections 236 
from dendritic segments were captured for spine analysis performed with NeuronStudio 237 
software (Rodriguez et al., 2008) as described previously (Bertling et al., 2016).  238 
2.8 Statistical analyses 239 
Statistical analyses were performed using the SPSS (version 21.0) or GraphPad Prism (version 240 
5.02) software. A comparison of three or more groups was performed using one-way ANOVA 241 
followed by the Fisher’s least significant difference (LSD) post-hoc test or Dunnett’s test. 242 
Statistical significance between two groups was tested using the independent sample t-test. All 243 
values are reported as mean + standard error of mean (SEM). The level of statistical 244 
significance was defined as p<0.05.  245 
246 
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3. Results 247 
3.1 HMI-1a3 reduces neuronal loss after LPS+IFN-γ-induced neuroinflammation in mouse 248 
primary neuron-BV2 microglia co-cultures  249 
Mouse primary neuron-BV2 microglia co-cultures have been previously used to study the 250 
effects of LPS+IFN-γ-induced neuroinflammation (Martiskainen et al., 2017). Similarly, we 251 
observed a significant reduction in the neuronal viability after LPS+IFN-γ treatment as 252 
compared to vehicle treated co-cultures at DIV7 (Fig. 1a). The reduction in neuronal viability 253 
was accompanied with significantly increased levels of the proinflammatory cytokine TNFα 254 
and nitric oxide (NO) measured from the co-culture medium 48 hours after the initiation of 255 
LPS+IFN-γ treatment. Pre-treatment of co-cultures with the specific iNOS inhibitor 1400W 256 
resulted in an average of 85% reduction in NO levels and reduced neuronal loss, without 257 
affecting the levels of TNFα (Fig. 1a). However, pre-treatment of co-cultures with IL-10 258 
significantly decreased the TNFα levels in LPS+IFN-γ-treated cells by 60%, without effects on 259 
neuronal viability or the levels of NO (Fig. 1a). LPS+IFN-γ treatment of mouse primary 260 
cortical neuronal cultures without addition of BV2 microglial cells did not affect the production 261 
of TNFα or NO, or neuronal viability as compared to vehicle treated samples (data not shown). 262 
Collectively, these results are consistent with the previous findings in the neuron-BV2 263 
microglia co-cultures upon neuroinflammation (Martiskainen et al., 2017) and thus corroborate 264 
the usage of this co-culture system as a feasible model to investigate protein kinase C-activating 265 
isophthalate derivatives in the cellular processes relevant for AD, such as neuroinflammation.     266 
To investigate whether HMI-1a3 and HMI-1b11 exert neuroprotective effects, we 267 
administered the test compounds with or without the pan-PKC inhibitor Gö6983 into the co-268 
culture medium 1 h after the addition of BV2 microglial cells into neuronal cultures. NI-15e, 269 
which is a structural analogue of HMI-1a3 without significant affinity to the C1 domain, was 270 
used as a negative control as well as PMA and bryostatin-1 as positive controls for PKC 271 
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activation. Neuroinflammation was induced 1 h later with LPS+IFN-γ. HMI-1b11 had no effect 272 
on neuronal viability (data not shown), whereas HMI-1a3 increased neuronal viability upon 273 
LPS+IFN-γ treatment, especially at 20 µM concentration as compared to vehicle treated cells 274 
(Fig. 1b). Interestingly, the PKC inhibitor Gö6983 alone (1 µM) did not affect neuronal 275 
viability, but neuronal loss was observed, when it was administered in combination with any 276 
of the HMI-1a3 concentrations studied (Fig. 1b). Unexpectedly, the negative control NI-15e 277 
induced approximately 20% neuronal loss at all concentrations as compared to the vehicle 278 
control. Similarly, the potent PKC activator PMA reduced neuronal viability significantly at 279 
both 10 nM and 100 nM concentrations, and this effect was not affected by simultaneous PKC 280 
inhibition with Gö6983 (Fig. 1c). Bryostatin-1, another PKC activator, had no effect on 281 
neuronal viability alone, while in combination with Gö6983, it increased the neuronal viability 282 
(Supplementary Fig. S1a). Taken together, these results suggest that HMI-1a3 exhibits 283 
neuroprotective activity in neuron-BV2 microglial co-cultures subjected to LPS+IFN-γ-284 
induced neuroinflammation.  285 
3.2 HMI-1a3 treatment decreases the levels of TNFα but does not affect NO production in 286 
mouse primary neuron-BV2 microglia co-cultures subjected to neuroinflammation  287 
It is well-established that several microglia-activating cascades, including Aβ deposition, 288 
initiate neuroinflammation in brain. Activated microglia play an important role in the brain 289 
tissue by inducing the expression of pro-inflammatory cytokines, such as interleukins and 290 
TNFα, which in turn trigger the expression of inducible nitric oxide synthase (iNOS) and the 291 
production of NO (Wang et al., 2015). In neurons, TNFα and NO act as important mediators 292 
with both pro-inflammatory and destructive effects. HMI-1a3 decreased TNFα levels in a 293 
concentration-dependent manner as compared to vehicle treated cells (Fig. 2a). However, HMI-294 
1a3 had no effect on TNFα production in the presence of 1µM Gö6983, indicating that the 295 
HMI-1a3-induced decrease in TNFα secretion was mediated by PKC. As with HMI-1a3, 296 
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bryostatin-1 alone decreased TNFα levels, while this effect was not reversed in the presence of 297 
Gö6983 (Supplementary Fig. S1b). As expected, NI-15e had no effect on the levels of TNFα 298 
upon LPS+IFN-γ-induced neuroinflammation (Fig. 2a). In contrast with the effects of HMI-299 
1a3, the treatment of co-cultures with 100 nM PMA increased the levels of TNFα both alone 300 
and in the presence of Gö6983 (Fig. 2b), which is in line with its PKC-independent neurotoxic 301 
effects in the ABTS assay. Neither HMI-1a3 nor NI-15e had any effect on the production of 302 
NO in LPS+IFN-γ-treated co-cultures (Fig. 2c). Similarly, PMA alone had no effect on 303 
production of NO, but when co-administered with 1µM Gö6983, it increased the NO 304 
production at both 10 nM and 100 nM concentrations (Fig. 2d). Conversely, bryostatin-1 305 
increased the production of NO in a PKC activation-dependent manner (Supplementary Fig. 306 
S1c). In summary, HMI-1a3 decreased the levels of TNFα through activation of PKC, but did 307 
not affect the production of NO. 308 
 309 
3.3 HMI-1a3 does not affect the S536 phosphorylation of NFB p65 in the primary neuron-310 
BV2 microglia co-cultures upon neuroinflammation 311 
Since nuclear factor kappa B (NFB) is the key transcriptional regulator of genes that control 312 
inflammation, immune regulation, proliferation and cell death (Christian et al., 2016), we next 313 
assessed the phosphorylation status and the total levels of NFB p65 subunit in the primary 314 
neuron-BV2 microglia co-cultures treated with HMI-1a3 or bryostatin-1 upon 315 
neuroinflammation (Fig. 3). The S536 phosphorylation site in NFB p65 subunit was selected 316 
as it is one of the best-understood phosphorylation targets in the transactivation domain 317 
(Christian et al., 2016). Primary neuron-BV2 microglia co-cultures were treated with 20 μM 318 
HMI-1a3, which in the previous experiments affected significantly neuronal viability and the 319 
levels of TNFα upon LPS+IFN-γ-induced neuroinflammation (Fig. 1b and Fig. 2a). Bryostatin-320 
1 (10 and 100 nM) was used as a control and all the LPS+IFN-γ-treated samples showed the 321 
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expected increase in the levels of NO, confirming the induction of neuroinflammation in the 322 
co-cultures (data not shown). Western blot analysis of total protein lysates of HMI-1a3- or 323 
bryostatin-1-treated samples upon LPS+IFN-γ-induced neuroinflammation did not reveal 324 
statistically significant changes in the S536 phosphorylation status of NFB p65 when 325 
normalized to the total levels of NFB p65 (Fig. 3a and Fig. 3b). HMI-1a3, but not bryostatin-326 
1, significantly increased the total levels of NFB p65 on average by 20% (Fig. 3a and Fig. 327 
3b). These results suggest that HMI-1a3 does not affect the S536 phosphorylation status in the 328 
transactivation domain of NFB p65 but instead increases moderately the levels of total NFB 329 
p65 in the primary neuron-BV2 microglia co-cultures upon neuroinflammation. 330 
3.4 HMI-1a3 and HMI-1b11 do not significantly affect the levels of Aβ40 or Aβ42 in primary 331 
neuron-BV2 microglia co-cultures upon neuroinflammation or in neuroblastoma cells 332 
We next elucidated whether the isophthalate derivatives affect the levels of Aβ40 and Aβ42, 333 
or the ratio of these Aβ species in the primary neuron-BV2 microglia co-culture media upon 334 
neuroinflammation. HMI-1a3 did not significantly affect the levels of Aβ40 (Fig. 4a) or Aβ42 335 
(Fig. 4b), nor the ratio of Aβ42/Aβ40 (Fig. 4c) as compared to vehicle-treated cells. However, 336 
there was a trend towards increased levels of Aβ40 and Aβ42, which prompted us to investigate 337 
whether the isophthalate derivatives affect APP processing in human SH-SY5Y neuroblastoma 338 
cells overexpressing APP751 (SH-SY5Y-APP751). In our previous study with naïve SH-339 
SY5Y cells, both HMI-1a3 and HMI-1b11 were shown to promote neurite growth, while HMI-340 
1b11 was better tolerated (Talman et al., 2013). Upon treatment with HMI-1a3 or HMI-1b11 341 
for 48 h, both Aβ40 and Aβ42 levels in the cell culture medium showed a moderate, but non-342 
significant increase when compared to vehicle-treated control cells (Fig. 4d). In addition, the 343 
ratio of Aβ42/Aβ40 was moderately, but not statistically significantly decreased (Fig. 4f). 344 
However, 10 nM PMA, which was used as a positive control, caused a significant increase in 345 
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the levels of Aβ40 (Fig. 4d), without any effect on the levels of Aβ42 (Fig. 4e), leading to a 346 
~70% decrease in the ratio of Aβ42/Aβ40 as compared to a vehicle-treated cells (Fig. 4f). This 347 
is in line with numerous previous studies showing increased α-secretase-mediated APP 348 
cleavage in response to PKC activation with phorbol esters (Skovronsky et al., 2000; Zhu et 349 
al., 2001). 10 nM bryostatin-1 did not affect the levels of Aβ40, but it decreased the levels of 350 
Aβ42, thereby significantly decreasing the ratio of Aβ42/Aβ40 (Supplementary Fig. S2). No 351 
effects were observed with the treatment of 100 nM bryostatin-1 (Supplementary Fig. S2). 352 
Although we observed a trend towards a decreased ratio of Aβ42/Aβ40 in cells treated with the 353 
isophthalate derivatives, these results suggest that the isophthalates are not as effective as PMA 354 
or bryostatin-1 in modulating the APP processing towards the non-amyloidogenic pathway.  355 
3.5 HMI-1a3 affects the levels of APP C83 and the maturation of APP in neuroblastoma 356 
cells  357 
Next, we explored the effects of these PKC activators on the levels and maturation of APP and 358 
APP C-terminal fragment (APP C83) in SH-SY5Y-APP751 cells after 4- (Fig. 5a-b) and 24-359 
hour (Fig. 5c-d) treatments. Additionally, the γ-secretase inhibitor DAPT (10 µM) was used as 360 
a positive control in combination with PMA (10 nM) to induce accumulation of C-terminal 361 
fragments, especially APP C83 (indicated as PMA+DAPT in Fig. 5). A 4-h treatment with 362 
HMI-1a3 decreased, while a 24-h treatment with HMI-1a3, HMI-1b11, and PMA increased the 363 
levels of APP C83 significantly in SH-SY5Y-APP751 cells as compared to vehicle-treated 364 
cells. Importantly, the increase in APP C83 in 24-h treatment samples coincided with the 365 
increased levels of total APP (APPtot) with all treatments (Fig. 5d). A similar increase in the 366 
levels of APPtot was not observed in the 4-h treated samples, except with PMA+DAPT (Fig. 367 
5b). A statistically significant increase in the levels of immature APP (APPim) and a concurrent 368 
decrease in the levels of mature APP (APPm) was observed after a 4-h treatment with HMI-1a3 369 
(Fig. 5b). The PKC activators HMI-1a3, HMI-1b11 and PMA induced statistically significant 370 
17 
decreases in the ratio of APPm/APPim after both 4-h and 24-h treatments (Figs. 5b and 5d, 371 
respectively), suggesting that treatment with PKC activators inhibited the maturation of APP. 372 
Bryostatin-1 did not induce statistically significant changes in the maturation of APP after 4-h 373 
or 24-h treatments (Supplementary Fig. S4). Collectively, these results suggest that both 374 
isophthalate derivatives decrease the maturation of APP in neuroblastoma cells.    375 
3.6 HMI-1a3 and HMI-1b11 increase the levels of secreted sAPPα relative to total sAPP in 376 
neuroblastoma cells 377 
As we observed significant changes in the processing and maturation of APP in SH-SY5Y-378 
APP751 cells treated with HMI-1a3 and HMI-1b11, we next assessed whether these 379 
compounds affect the soluble APPα (sAPPα) and the total soluble APP (sAPPtot) levels in the 380 
cell culture medium (Fig. 6a-b and Fig. 6c-d). After a 24-h treatment, a statistically significant 381 
increase in sAPPα levels was observed with all compounds as compared to vehicle-treated cells 382 
(Fig. 6d). A similar trend towards increased levels of sAPPα was observed after a 4-h treatment 383 
with all compounds except with HMI-1a3. In contrast to sAPPα levels, approximately 40% 384 
decrease in the levels of sAPPtot was observed after a 4-h treatment with both HMI-1a3 385 
(p=0.06) and HMI-1b11 (p<0.05) as compared to vehicle-treated cells (Fig. 6b). Due to the fact 386 
that the levels of APPtot were affected, particularly after a 24-hour treatment (Fig. 5d), we 387 
quantified the ratio of sAPPα and sAPPtot (sAPPα/sAPPtot). Both HMI-1a3 and HMI-1b11 388 
increased the ratio of sAPPα/sAPPtot after 4-h and 24-h treatments as compared to the vehicle-389 
treated cells. PMA alone and in combination with DAPT (PMA+DAPT) increased the ratio of 390 
sAPPα/sAPPtot significantly after 4 h, but not after 24 h. A similar trend was seen with 391 
bryostatin-1, although the results were not statistically significant (Supplementary Fig. S4). 392 
This may relate to the fact that PMA and PMA+DAPT have a more robust effect on the levels 393 
of sAPPtot as compared to HMI-1a3 and HMI-1b11. This difference between isophthalates and 394 
PMA may be due to the down-regulation of PKC after the 24-h PMA exposure, a phenomenon 395 
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which is not seen in response to isophthalate treatment (Supplementary Fig. S5). Collectively, 396 
these findings suggest that HMI-1a3 and HMI-1b11 promote non-amyloidogenic APP 397 
processing and the secretion sAPPα relative to the levels of sAPPtot.  398 
3.7 The PKC activator bryostatin-1 increases the number of mushroom spines in mouse 399 
mature hippocampal neuron cultures  400 
PKC isoforms are located within hippocampal dendritic spines and they are known to play a 401 
role in the modulation of dendritic spine morphology (Alkon et al., 2007; Calabrese and 402 
Halpain, 2005). Therefore, the role of PKC activators HMI-1a3 (10 µM) and bryostatin-1 (100 403 
nM) were investigated in mature primary mouse hippocampal neurons (DIV20) in a short-term 404 
2-h treatment. As a result, total spine density, stubby spine density, and thin spine density 405 
decreased significantly with bryostatin-1 as compared to vehicle treated cells (Fig. 7a). In 406 
contrast, a moderate non-significant increase in total, mushroom, stubby, and thin spine 407 
densities was observed after HMI-1a3 treatment (Fig. 7a). Analysis of spine head morphology 408 
revealed that the 2-h exposure of hippocampal neurons to HMI-1a3 was not able to modify the 409 
shape of the spine head, while bryostatin-1 significantly increased the diameter of mushroom 410 
and stubby spine heads and decreased the diameter of thin spine heads (Fig. 7b). Overall, 411 
HMI-1a3 did not significantly modify the number of mushroom, stubby, or thin spine head 412 
morphology, whereas bryostatin-1 treatment increased the mushroom spine head density and 413 
decreased the thin spine head density in ratio to total number of spine heads (Fig. 7c). 414 
Collectively, these data suggest that bryostatin-1 supports stabilization of spine heads towards 415 
the mature, active mushroom-like shape. 416 
 417 
 418 
 419 
 420 
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4. Discussion 421 
Dysregulation in PKC activation has been shown to associate with many pathophysiological 422 
features of AD, including memory loss, increased levels of Aβ and β-amyloid plaques, 423 
neurofibrillary tangles as well as neuroinflammation, and PKC activators have therefore been 424 
suggested to represent promising drug candidates for the treatment of AD (Alkon et al., 2007; 425 
Sun and Alkon, 2012). Furthermore, several PKC activators, such as DAG-lactones and 426 
bryostatins, have been shown to alleviate pathophysiological hallmarks of AD in both in vitro 427 
and in vivo models (reviewed in (Talman et al., 2016)). Here, we report for the first time the 428 
effects of PKC C1 domain ligands, 5-(hydroxymethyl) isophthalate derivatives HMI-1a3 and 429 
HMI-1b11 in different in vitro models of relevant for AD. The key findings of the study are 430 
that HMI-1a3 enhances neuronal viability and reduces the production of TNFα in the neuron-431 
BV2 microglia co-cultures upon LPS- and IFN-γ-induced neuroinflammation. These changes 432 
were not associated with significant alterations in the S536 phosphorylation status in the 433 
transactivation domain of NFB p65 subunit. Instead, the total levels NFB p65 were 434 
moderately increased owing to HMI-1a3 treatment in the neuron-BV2 microglia co-cultures 435 
upon neuroinflammation. Furthermore, both HMI-1a3 and HMI-1b11 altered processing and 436 
maturation of APP as well as the levels of soluble APPα in SH-SY5Y neuroblastoma cells. 437 
Finally, we demonstrate that bryostatin-1, but not HMI-1a3, increases the number of mushroom 438 
spines in mature mouse hippocampal primary neuronal cultures upon basal conditions. These 439 
data suggest that the isophthalate derivatives can reduce neuroinflammation and promote 440 
neuronal survival to some extent in in vitro. Therefore, it is justified to continue the assessment 441 
of potential neuroprotective effects as well as the underlying molecular mechanisms of these 442 
derivatives e.g. in the in vivo models relevant for AD in the future.    443 
 Insufficient PKC activation has been associated with abnormalities in neuroinflammatory 444 
signaling (Alkon et al., 2007), a phenomenon characteristic in the early pathophysiology of AD 445 
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(Tarkowski et al., 2003). Furthermore, the levels and activity of PKC isoforms is attenuated in 446 
the brain of AD patients (Lucke-Wold et al., 2015; Wang et al., 1994). In line with these 447 
observations, encouraging results on the effects of PKC activators in both in vitro and in vivo 448 
models of AD have been reported (Talman et al., 2016). Many of the positive effects induced 449 
by PKC activators have been attributed to the activation of isoforms ε and γ (Lucke-Wold et 450 
al., 2015), which has evoked ideas about specifically targeting these isoforms. However, most 451 
of the studies on PKC activators have been done with activators that are not isoform specific, 452 
such as bryostatin-1. Similar to bryostatin-1, HMI-1a3 binds to the C1-domain of both novel 453 
and classical isoforms of PKC and is therefore not isoform-specific. Furthermore, as Gö6983 454 
inhibits several PKC isoforms (Gschwendt et al., 1996), identification the exact isoform(s) 455 
responsible for HMI-1a3-induced effects reported here, requires further investigations. 456 
 PKC activation has been shown to direct APP processing towards the production of 457 
neuroprotective sAPPα in several cell-based models and restoration of synapses has been 458 
reported in both cells as well as in rodents with various PKC activators (Talman et al., 2016). 459 
The PKC activator bryostatin-1 has been shown to improve memory in behavioral tests in 460 
several rodent models and has progressed to clinical trials as the first PKC-targeted therapy for 461 
neurodegenerative diseases (www.clinicaltrials.gov) (Talman et al., 2016). Although PKC 462 
activators have been traditionally considered as tumor promoters, this view has been challenged 463 
by a recent comprehensive study, which showed that the majority of cancer-associated PKC 464 
mutations were loss-of-function mutations and none were activating (Antal et al., 2015). The 465 
tumor-promoting properties of some PKC activators, such as the phorbol esters, may thus in 466 
fact be due to PKC down-regulation and not increased activity per se. Therefore, it appears that 467 
the loss of PKC activity might lead to tumor promotion, which makes the development drugs 468 
that are partial agonists even more appealing.   469 
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 In the present study, we found that HMI-1a3 promoted to some extent neuronal survival 470 
effects in the primary neuron-BV2 microglial cell co-cultures upon LPS-IFN-γ-induced 471 
neuroinflammation. In the presence of PKC inhibitor Gö6983 (1µM), the neuroprotective 472 
effect of HMI-1a3 was abolished implicating that the effect was PKC-dependent. Surprisingly, 473 
viability of neurons decreased when cells were treated with both compounds, whereas Gö6983 474 
alone had no effect on neuronal viability. This may relate to fact that in addition to PKC, six 475 
other protein families, such as Munc13, protein Kinase D (PKD), RasGRP, chimaerins, 476 
diacylglycerol kinases (DAGKs) and myotonic dystrophy kinase-related Cdc42-binding kinase 477 
(MRCK), contain analogous C1 domains and consequently HMI-1a3 has been shown to bind 478 
to several of these (Talman et al., 2014). Therefore, it is possible that HMI-1a3 could modulate 479 
some C1 domain-dependent pathways that counteract PKC signalling, which would then lead 480 
to compromised neuronal viability when PKC is inhibited by Gö6983. Furthermore, Gö6983 481 
binds to the ATP binding site of PKC (Wu-Zhang and Newton, 2013) and not to the C1 domain, 482 
and therefore does not affect the activity of other C1 domain containing proteins. The potent 483 
PKC activator PMA reduced neuronal viability significantly at both 10 nM and 100 nM 484 
concentrations, and this was not affected by the pan-PKC inhibitor Gö6983. PMA, like 485 
isophthalates, also have other targets besides PKC and the observed reduction in neuronal 486 
viability with PMA in combination with Gö6983, could be due to activation of these other 487 
target proteins. The observation that both HMI-1a3 and PMA caused a decrease in neuronal 488 
viability when used in combination with Gö6983 supports the notion that other C1-domain 489 
containing proteins are likely to be responsible for this outcome. Furthermore, the difference 490 
in the response to these compounds alone could be explained by the level of PKC activation 491 
they induce. Too robust and prolonged activation by PMA leads to the downregulation of PKC 492 
protein levels and a decrease in neuronal viability, whereas HMI-1a3 induces PKC activation 493 
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without causing downregulation. Thus, the results suggest that the activation of PKC without 494 
downregulation is neuroprotective upon LPS-IFN-γ-induced neuroinflammation.  495 
 The effect of HMI-1a3 on neuronal viability could be explained by its effect on TNFα. 496 
HMI-1a3 concentration-dependently reduced the levels of TNFα and this effect was abolished 497 
with Gö6983, suggesting that the effect was mediated by PKC. PMA had no effect on the TNFα 498 
levels at 10 nM concentration but induced an increase at 100 nM. At 100 nM concentration and 499 
after a 48-h exposure PMA already downregulates PKC, while still activating other targets 500 
containing a phorbol-responsive C1 domain. For example, activation of Munc-13 has been 501 
shown to positively regulate TNFα release in macrophages (Mori et al., 2011). When PMA 502 
was combined with Gö6983, the increase in the levels of TNFα could be detected already at 503 
the 10 nM PMA concentration. It is possible that PKC activation with 10 nM PMA 504 
concentration counteracts the PKC-independent effects of PMA and when PKC activation is 505 
inhibited with Gö6983, this PKC-independent effect becomes dominant. Slightly in contrast 506 
with these PMA results, but in line with the effect of HMI-1a3, bryostatin-1 decreased the 507 
levels of TNFα. However, this effect was not abolished, but instead was potentiated by PKC 508 
inhibition, indicating that also other targets of bryostatin-1 may contribute to the observed 509 
decrease in the production of TNFα. To elucidate the potential molecular mechanism 510 
underlying the increased neuronal viability and the reduced levels of TNFα owing to HMI-1a3, 511 
we determined the S536 phosphorylation status in the transactivation domain of NFB p65 512 
subunit (Christian et al., 2016), and the levels of total NFB p65 in the primary neuron-BV2 513 
microglia co-cultures upon neuroinflammation. It is a well-established observation that the 514 
increased S536 phosphorylation leads to the enhanced transactivation of NFB via the 515 
increased binding of CREB-binding protein/p300 and acetylation at K310 of NFB p65 (Chen 516 
et al., 2005). Consequently, the activated nuclear NFB mediates gene transcription of certain 517 
chemokines and interleukins, such as TNFα, IFNγ and IL6, known to play a central role in the 518 
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immune response, proliferation, and cell death. However, we did not find any significant 519 
changes in the phosphorylation status of S536 in NFB p65, but instead we observed a 520 
moderate, but statistically significant increase in the total levels of NFB p65 in the co-cultures 521 
treated with HMI-1a3 upon neuroinflammation. Interestingly, bryostatin-1 did not have any 522 
significant effects on phosphorylation status or total levels of NFB p65 upon 523 
neuroinflammation. The relevance of the increased levels of NFB p65 subunit (~20%) owing 524 
to HMI-1a3 treatment is not clear and thus further studies are needed to elucidate whether this 525 
relatively small increase would play a prominent role in terms of neuroprotection. Conversely, 526 
it should be noted that the increased levels of NFB p65 did not lead to the augmentation of 527 
S536 phosphorylation in NFB p65 subunit, suggesting that enhanced transactivation of NFB 528 
did not take place after HMI-1a3 treatment upon neuroinflammation. Although the S536 529 
phosphorylation site in NFB p65 is one of the best-understood phosphorylation targets in the 530 
transactivation domain of NFB p65 (Christian et al., 2016), we cannot rule out the possibility 531 
that some other phosphorylation target in NFB known to control NFB-directed 532 
transactivation could be affected by HMI-1a3 or bryostatin-1 upon neuroinflammation. Despite 533 
the observed compound-induced changes in the levels of TNFα upon neuroinflammation, we 534 
did not observe major effects on the production of NO. The observation that PMA increases 535 
the production of NO only in conditions where PKC is inhibited, may suggest that the effect is 536 
again mediated by another C1 domain-containing protein, which under normal conditions is 537 
suppressed by PKC activity. For example, PKD has been reported to directly activate neuronal 538 
NO synthase (Sánchez-Ruiloba et al., 2014). Collectively, these results suggest that HMI-1a3 539 
may exert neuroprotection by activating PKC, and this is probably mediated by alleviating the 540 
production of proinflammatory cytokine TNFα upon LPS+IFN-γ-induced neuroinflammation 541 
in neuron-BV2 cell co-cultures. As neuroinflammation is considered a central detrimental 542 
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phenomenon in AD and other neurodegenerative diseases, this anti-inflammatory and 543 
neuroprotective effect of HMI-1a3 is very encouraging.  544 
PKC activators, such as phorbol esters and bryostatin-1, have previously been shown to 545 
reduce Aβ40 and Aβ42 levels in in vivo models of AD (Etcheberrigaray et al., 2004; Savage et 546 
al., 1998). In contrary to this, we did not observe significant effect on Aβ40 or Aβ42 levels in 547 
neuron-BV2 co-cultures when treated with HMI-1a3 or HMI-1b11. However, both isophthalate 548 
derivatives induced a moderate, but non-significant decrease in Aβ42/Aβ40 ratio in SH-SY5Y-549 
APP751 cells. This was confirmed to be a consistent outcome as we observed a significant 550 
increase in the levels of APP C83, decrease in APPm/APPim ratio, and an increase in 551 
sAPPα/sAPPtot ratio in SH-SY5Y-APP751 cells when the cells were treated with HMI-1a3 or 552 
HMI1b11 for 24 h. Additionally, as both APPm and APPim levels were increased after 553 
isophthalate treatment for 24 h, it can be speculated that isophthalate-induced PKC activation 554 
might enhance post-translational modification of APP, such as glycosylation, sulfation, and 555 
phosphorylation during transit through the intracellular protein secretory pathway (da Cruz e 556 
Silva et al., 2009). Indeed, PKC has been reported to not only directly phosphorylate APP, but 557 
also regulate its trafficking by controlling the formation of APP bearing vesicles in the Trans-558 
Golgi network (TGN) (Gandy et al., 1988; Xu et al., 1995). In addition, PKC activation has 559 
been shown to increase the transcription of APP already after 3 h, and induce a 4-fold increase 560 
in the APP mRNA levels after a 24-h exposure to PMA (100 nM) (Trejo et al., 1994), which is 561 
in line with our finding that total APP levels were increased at 24 h in response to the 562 
isophthalates, PMA and also to some extent bryostatin-1. Previous studies have indicated that 563 
the cellular responses to PKC-activating compounds are dependent on the exposure time. Acute 564 
PKC activation has been reported to increase the release of sAPPα by activating α-secretase, 565 
while chronic exposure to PKC activators has also increased the expression levels of APP (da 566 
Cruz e Silva et al., 2009; Trejo et al., 1994). Furthermore, da Cruz de Silva et al (2009) reported 567 
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that a 24-h exposure to phorbol ester increased total APP production, decreased sAPPα, 568 
increased Aβ levels and caused accumulation of APP in TGN. However, most of these 569 
phenomena were explained by PKC downregulation. The isophthalate derivatives do not 570 
induce PKC down-regulation within 24 h in SHSY5Y cells, and although the accumulation of 571 
APP in TGN was visible after 24-h exposure, the sAPPα/sAPPtot ratio was still increased with 572 
isophthalates, unlike with PMA. Notably, the increased levels of both APP C83 and sAPPα, 573 
but not that of sAPPtot suggest that the exposure to different PKC agonist might specifically 574 
promote the accumulation of APP at the cell surface and influence the recycling of re-575 
internalized APP back to the plasma membrane, where majority of the non-amyloidogenic α-576 
cleavage takes place. Our findings support the idea that activation of PKC may increase the 577 
levels of sAPPα by mechanisms involving the formation and release of secretory vesicles from 578 
the TGN, thus enhancing APP trafficking to the cell surface (Thinakaran and Koo, 2008; Xu 579 
et al., 1995). Since sAPPα is neuroprotective, the sustained increase in its production 580 
(sAPPα/sAPPtot ratio) achieved with isophthalates, but not with PMA, further supports the 581 
idea that activating PKC, without inducing its downregulation, may represent a promising 582 
therapeutic strategy for AD.   583 
We also detected increased mushroom spine density relative to total spine density in the 584 
mature mouse hippocampal neurons upon basal growth conditions after a 2-h treatment with 585 
PKC activator bryostatin-1, suggesting that PKC activation increases the number of functional 586 
excitatory post-synaptic terminals. To support this, we also observed a significant increase in 587 
mushroom spine head diameter in bryostatin-1-treated hippocampal neurons, indicating that 588 
enlargement of mushroom spine head through activation of PKC signaling cascade may lead 589 
to formation of a postsynaptic density in dendritic mushroom spine as previously reported 590 
(Calabrese and Halpain, 2005; Sen et al., 2016; Yoshihara et al., 2009). In this study, HMI-1a3 591 
did not affect spine morphology. This could be due to the relatively short treatment time, which 592 
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is probably enough to induce changes with a very potent PKC activator, such as bryostatin-1, 593 
but might not be long enough for less potent activators, such as the isophthalates. Whether 594 
longer isophthalate treatments would affect spine morphology remains to be determined. 595 
Moreover, these experiments were carried out in basal conditions without induction of 596 
neuroinflammation. Isophthalates appear to promote neuroprotection by alleviating 597 
inflammation and therefore it would be interesting to see, if they could affect the morphology 598 
of the spines or protect them upon neuroinflammation. However, the changes observed with 599 
bryostatin-1 by us and others (Hongpaisan et al., 2013; Sen et al., 2016) reinforce the need of 600 
further investigation of C1-domain binding PKC activators and suggest that activation of PKC 601 
could be a promising strategy for treating neurodegenerative diseases, such as AD.  602 
Taken together, these studies conducted in several different in vitro cellular models and 603 
conditions, suggest that C1 domain-binding PKC activators affect various molecular processes 604 
related to neuronal survival and processing and maturation of APP, which are all known to play 605 
a role in the pathophysiology of AD. However, further research is required to determine the in 606 
vivo efficacy of isophthalate derivatives in AD-related neurodegeneration.  607 
 608 
5. Conclusions 609 
In summary, our data suggest that the PKC-activating isophthalate derivatives show 610 
neuroprotective activity against neuroinflammation-induced toxicity in vitro, possibly through 611 
the attenuation of cytotoxic microglia-derived production of TNFα in the neuron-microglia co-612 
cultures. Furthermore, the isophthalate derivatives promoted non-amyloidogenic processing 613 
and maturation of APP by enhancing its post-translational modification at the secretory 614 
pathway and by increasing the α-cleavage of APP in SH-SY5Y-APP751 cells. Together with 615 
previous reports, our findings suggest that the synthetic isophthalate derivatives and other PKC 616 
agonists, such as bryostatin-1, may exert neuroprotective effects in various stress conditions 617 
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associated with AD and other neurodegenerative diseases. Thus, the isophthalate derivatives 618 
may be considered potential candidates in the search of new therapeutic strategies against 619 
synaptic dysfunction and neurodegeneration known to take place in AD. 620 
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Figure legends 843 
Figure 1. HMI-1a3 reduces neuronal loss upon LPS+IFN-γ-induced neuroinflammation 844 
in mouse primary neuron-BV2 microglia co-cultures. (A) Characterization of the mouse 845 
primary cortical neuron and BV2 microglial cell co-cultures and effects upon LPS+IFN-γ-846 
induced neuroinflammation. (B) Effects of HMI-1a3 alone and in combination with 1 µM 847 
Gö6983 on neuronal viability upon LPS+IFN-γ-induced neuroinflammation. NI-15e was used 848 
as a negative control for HMI-1a3. (C) Effects of PMA alone and in combination with Gö6983 849 
on neuronal viability. (#)-sign indicates the statistical difference compared between same 850 
concentration of HMI-1a3 and HMI-1a3 + 1 µM Gö6983 samples, and (*)-sign indicates the 851 
statistical difference compared between the treated sample and a vehicle treated (0 µM) sample 852 
within the group. One-way ANOVA and independent samples t-test, */#p<0.05, **/# #p<0.01, 853 
***/# # #p<0.001, mean+SEM, n=3-12; 0 µM = Vehicle (0.1% DMSO) + LPS+IFN-γ (± 854 
1 µM Gö6983). 855 
Figure 2. HMI-1a3 decreases the levels of TNFα but does not affect production of NO in 856 
mouse primary neuron-BV2 microglia co-cultures subjected to neuroinflammation. (A) 857 
Effects of HMI-1a3 alone and in combination with 1 µM Gö6983 on TNFα levels upon 858 
LPS+IFN-γ-induced neuroinflammation. NI-15e was used as a negative control for HMI-1a3. 859 
(B) Effects of PMA on the levels of TNFα alone and in combination with 1 µM Gö6983. (C) 860 
Effects of HMI-1a3 alone and in combination with 1 µM Gö6983 on the production of NO 861 
upon LPS+IFN-γ-induced neuroinflammation. NI-15e was used as a negative control for HMI-862 
1a3. (D) Effects of PMA on the production of NO alone and in combination with 1 µM Gö6983. 863 
(#)-sign indicates the statistical difference compared between same concentration of HMI-1a3 864 
and HMI-1a3 + 1 µM Gö6983 samples, and (*)-sign indicates the statistical difference 865 
compared between the treated sample and a vehicle sample within the group. One-way 866 
38 
ANOVA and independent samples t-test, LSD, */#p < 0.05, **/# #p < 0.01, ***p < 0.001, 867 
mean+SEM, n=4-16; 0 µM = Vehicle (0.1% DMSO) + LPS+IFN-γ (± 1 µM Gö6983).  868 
Figure 3. HMI-1a3 increases the levels of total NFB p65 in primary neuron-BV2 869 
microglia co-cultures upon neuroinflammation. Western blotting was used to analyse the 870 
levels of S536 phosphorylated NFB p65 (p-NFB p65) and total NFB p65 (Tot-NFB p65). 871 
(A) Representative blots and (B) quantification of the ratio of S536 phosphorylated NFB p65 872 
to total NFB p65 as well as the levels of total NFB p65 normalized to β-actin. Vehicle-873 
treated control sample is also shown from the same Western blot. One-way ANOVA followed 874 
by Dunnet’s test, *p < 0.05, mean+SEM, n=4; Vehicle = 0.1% DMSO. 875 
Figure 4. HMI-1a3 and HMI-1b11 do not significantly affect Aβ40 and Aβ40 levels in 876 
primary neuron-BV2 co-cultures upon neuroinflammation or in SH-SY5Y 877 
neuroblastoma cells. (A-C), The effects of HMI-1a3 on the levels of Aβ40 (A), Aβ42 (B) and 878 
the ratio of Aβ42/Aβ40 (C) in LPS+IFN-γ-treated neuron-BV2 co-cultures after 48 hours. (D-879 
F), The effects of 48-h treatments with HMI-1a3, HMI-1b11 and PMA on the levels of Aβ40 880 
(D) and Aβ42 (E) and the ratio of Aβ42/Aβ40 (F) in SH-SY5Y-APP751 cells. Data are 881 
represented as mean+SEM (One-way ANOVA followed by Dunnett’s test and independent 882 
samples t-test, LSD, *p < 0.05, mean+SEM, n=3-8; Vehicle = 0.1% DMSO; 0 µM = Vehicle 883 
+ LPS+IFN-γ). 884 
Figure 5. HMI-1a3 and HMI-1b11 inhibit the maturation of APP in SH-SY5Y 885 
neuroblastoma cells. Representative Western blot images (A and C) and quantifications (B 886 
and D) indicating the effects of HMI-1b11, HMI-1a3, PMA, and co-treatment of PMA (10 nM) 887 
and γ-secretace inhibitor DAPT (10 µM) (PMA+DAPT) on APP C83, mature APP (APPm), 888 
immature APP (APPim), total APP (APPm+APPim) levels and APPm/APPim ratios in SH-889 
SY5Y-APP751 cells after 4-hour (A-B) and 24-hour (C-D) treatment. The representative 890 
39 
Western blot image for the APP C83 fragment from 24-hour treatment (C) is presented as two 891 
images from the same blot, with and without PMA+DAPT treated samples. To make the bands 892 
of interest more visible, contrast and intensity were adjusted in the image omitting the PMA-893 
DAPT-treated samples. The quantification values represent optical densities normalized to the 894 
GAPDH levels and are shown as % of vehicle control (0.1% DMSO. The data are presented as 895 
mean+SEM (One-way ANOVA followed by Dunnett’s test and independent samples t-test, 896 
*p < 0.05, **p < 0.01, ***p < 0.001, n=4; N.S. = not statistically significant).  897 
Figure 6. HMI-1a3 and HMI-1b11 increase the levels of sAPPα relative to total sAPP in 898 
the cell culture medium of SH-SY5Y neuroblastoma cells. Representative Western blot 899 
images (A and C) and quantifications (B and D) indicating the effects of HMI-1a3, HMI-1b11, 900 
and PMA, or co-treatment of PMA (10 nM) and γ-secretace inhibitor DAPT (10 µM) 901 
(PMA+DAPT) on sAPPα and total sAPP (sAPPtot) levels in SH-SY5Y-APP751 cell culture 902 
medium after 4-hour (A-B) and 24-hour (C-D) treatment. The values are optical densities 903 
normalized to the total APP (APPm+APPim from the corresponding cell lysates, which is 904 
normalised to GAPDH) and are shown as % of vehicle control (0.1% DMSO). The data are 905 
presented as mean+SEM (n=4). One-way ANOVA followed by Dunnett’s test and independent 906 
samples t-test, **p < 0.01).  907 
Figure 7. The PKC activator Bryostatin-1 increases the number of mushroom spines after 908 
2-hour treatment in mature mouse hippocampal neuron cultures at DIV20. (A) The effects 909 
of 2-h treatments of bryostatin-1 (100 nM) or HMI-1a3 (10 µM) on total, stubby, and thin spine 910 
densities. (B) The effects of 2-h treatments with bryostatin-1 (100 nM) or HMI-1a3 (10 µM) 911 
on spine head morphology (width). (C) The effects of 2-h treatments with bryostatin-1 (100 912 
nM) or HMI-1a3 (10 µM) on mushroom and thin spine density ratio to total spine density. One-913 
40 
way ANOVA and independent samples t-test, *p < 0.05, **p < 0.01, ***p < 0.001, 914 
mean+SEM, n=14-33; Vehicle = 0.1% DMSO.  915 
 916 
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 918 
Figure S1. Bryostatin-1 decreases TNFα levels but has no effect on neuronal viability in 919 
mouse primary neuron-BV2 microglia co-cultures upon LPS+IFN-γ-induced 920 
neuroinflammation. Effects of bryostatin-1 alone and in combination with 1 µM Gö6983 on 921 
neuronal viability upon LPS+IFN--induced neuroinflammation (A), the levels of TNFα (B) 922 
and the production of NO (C) in mouse primary neuron-BV2 microglia co-cultures. One-way 923 
ANOVA followed by Dunnett’s test, *p < 0.05, **p < 0.01, ***p < 0.001, mean+SEM, n=6; 924 
0 µM = Vehicle (0.1% DMSO) + LPS+IFN-γ.  925 
 926 
Figure S2. PKC activation with bryostatin-1 decreases Aβ42 levels and Aβ42/Aβ40 ratio 927 
in mouse primary neuron-BV2 microglia co-cultures upon neuroinflammation. Effects of 928 
bryostatin-1 on Aβ40 and Aβ42 levels, and on the ratio of Aβ42/Aβ40 in mouse primary 929 
neuron-BV2 microglia co-cultures. One-way ANOVA followed by Dunnett’s test, *p < 0.05, 930 
mean+SEM, n=6; 0 µM = Vehicle (0.1% DMSO) + LPS+IFN-γ.  931 
 932 
Figure S3. Bryostatin-1 does not exhibit a significant effect on the maturation of APP in 933 
SH-SY5Y cells overexpressing APP751. Representative Western blot images (A and C) and 934 
quantifications (B and D) indicating the effects of bryostatin-1 on APP C83, mature APP 935 
(APPm), immature APP (APPim), and total APP (APPm+APPim) levels as well as 936 
APPm/APPim ratio in SH-SY5Y-APP751 cells after 4- (A and B) and 24-hour (C and D) 937 
treatments. The quantification values represent optical densities normalized to GAPDH and are 938 
41 
shown as % of vehicle control (0.1 % DMSO). The data are presented as mean+SEM from 939 
three independent experiments (One-way ANOVA followed by Dunnett’s test).  940 
 941 
Figure S4. Bryostatin-1 does not induce significant changes in the levels of sAPPα in SH-942 
SY5Y cells overexpressing APP751. Representative Western blot images (A and C) and 943 
quantifications (B and D), showing the effects of bryostatin-1 on sAPPα and total sAPP 944 
(sAPPtot) levels in SH-SY5Y-APP751 cell culture medium after 4-hour (A-B) and 24-hour (C-945 
D) treatments. The values are optical densities normalized to the total APP (APPm+APPim 946 
from the corresponding cell lysate, which is normalised to GAPDH) and are presented as % of 947 
vehicle control (0.1% DMSO) treatment. The data are presented as mean+SEM from three 948 
independent experiments (One-way ANOVA followed by Dunnett’s test).  949 
 950 
Figure S5. The levels of PKC isoforms α, βI, δ, and ε in SH-SY5Y neuroblastoma cells 951 
after 24-hour treatment with 100 nM PMA, 10 µM HMI-1a3 and 10 µM HMI-1b11. 952 
Densitometric analysis of Western blots (n=3). Results presented as mean+SEM. One-way 953 
ANOVA followed by Dunnett’s test and independent samples t-test (*p < 0.05, **p < 0.01, 954 
***p < 0.001).  955 
